General Hospital Celje, Department of Neurology, Oblakova Ulica 5, 3000 Celje, Slovenia.
General Hospital Celje, Department of Neurology, Oblakova Ulica 5, 3000 Celje, Slovenia.
Clin Neurol Neurosurg. 2023 May;228:107675. doi: 10.1016/j.clineuro.2023.107675. Epub 2023 Mar 14.
Alemtuzumab is a humanized monoclonal antibody indicated for treatment of highly active relapsing-remitting multiple sclerosis (HA-RRMS). It binds to CD52 antigen and produces a rapid and prolonged lymphocyte depletion followed by a different pattern of T and B cell repopulation. Among others, its adverse events are autoimmune diseases.In this article, we present a patient with HA-RRMS, who was subsequently treated with alemtuzumab and afterwards developed hemophagocytic lymphohistiocytosis (HLH). Albeit rarely, HLH can be triggered by alemtuzumab treatment.HLH can favourably respond to prompt immunosuppressant therapy.Multidisciplinary approach by a team consisting of a neurology, hematology and rheumatology specialist is needed to treat this potentially lethal condition.
阿仑单抗是一种人源化单克隆抗体，用于治疗高活性复发缓解型多发性硬化症（HA-RRMS）。它与 CD52 抗原结合，导致淋巴细胞迅速且持久耗竭，随后 T 和 B 细胞出现不同的再增殖模式。除此之外，其不良反应还有自身免疫性疾病。本文介绍了一位 HA-RRMS 患者，他随后接受了阿仑单抗治疗，随后发展为噬血细胞性淋巴组织细胞增生症（HLH）。尽管罕见，但阿仑单抗治疗可引发 HLH。HLH 可对及时的免疫抑制剂治疗产生有利反应。需要由神经病学、血液学和风湿病学专家组成的多学科团队来治疗这种潜在致命疾病。
